SG11202003565PA - Aromatic sulfonamide derivatives for the treatment of ischemic stroke - Google Patents

Aromatic sulfonamide derivatives for the treatment of ischemic stroke

Info

Publication number
SG11202003565PA
SG11202003565PA SG11202003565PA SG11202003565PA SG11202003565PA SG 11202003565P A SG11202003565P A SG 11202003565PA SG 11202003565P A SG11202003565P A SG 11202003565PA SG 11202003565P A SG11202003565P A SG 11202003565PA SG 11202003565P A SG11202003565P A SG 11202003565PA
Authority
SG
Singapore
Prior art keywords
treatment
ischemic stroke
sulfonamide derivatives
aromatic sulfonamide
aromatic
Prior art date
Application number
SG11202003565PA
Inventor
Peter Hauff
Stefan Werner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SG11202003565PA publication Critical patent/SG11202003565PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
SG11202003565PA 2017-10-29 2018-10-24 Aromatic sulfonamide derivatives for the treatment of ischemic stroke SG11202003565PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199070 2017-10-29
PCT/EP2018/079145 WO2019081573A1 (en) 2017-10-29 2018-10-24 Aromatic sulfonamide derivatives for the treatment of ischemic stroke

Publications (1)

Publication Number Publication Date
SG11202003565PA true SG11202003565PA (en) 2020-05-28

Family

ID=60191221

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003565PA SG11202003565PA (en) 2017-10-29 2018-10-24 Aromatic sulfonamide derivatives for the treatment of ischemic stroke

Country Status (16)

Country Link
US (1) US20210179577A1 (en)
EP (1) EP3700891A1 (en)
JP (1) JP2021501178A (en)
KR (1) KR20200081445A (en)
CN (1) CN111511720A (en)
AU (1) AU2018356430A1 (en)
BR (1) BR112020008484A2 (en)
CA (1) CA3079469A1 (en)
CL (1) CL2020001139A1 (en)
EA (1) EA202091028A1 (en)
IL (1) IL274041A (en)
JO (1) JOP20200077A1 (en)
MA (1) MA50448A (en)
MX (1) MX2020004472A (en)
SG (1) SG11202003565PA (en)
WO (1) WO2019081573A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102388962B1 (en) * 2016-05-03 2022-04-27 바이엘 파마 악티엔게젤샤프트 Aromatic sulfonamide derivatives
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CA3188308A1 (en) 2020-06-30 2022-01-06 Bayer Aktiengesellschaft Substituted n-phenylacetamides having p2x4 receptor antagonistic activity
WO2022049253A1 (en) 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
CN116635020A (en) * 2021-01-27 2023-08-22 武汉朗来科技发展有限公司 Aromatic compound, preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
HRP20211973T1 (en) * 2009-09-03 2022-03-18 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
JP2013523658A (en) 2010-03-26 2013-06-17 グラクソ グループ リミテッド Pyrazolyl-pyrimidines as kinase inhibitors
NZ604306A (en) 2010-05-17 2015-02-27 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2015088565A1 (en) 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds and methods of use thereof
WO2015088564A1 (en) 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds
CA2988637A1 (en) * 2015-06-10 2016-12-15 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
KR102388962B1 (en) * 2016-05-03 2022-04-27 바이엘 파마 악티엔게젤샤프트 Aromatic sulfonamide derivatives

Also Published As

Publication number Publication date
CL2020001139A1 (en) 2020-10-23
JP2021501178A (en) 2021-01-14
WO2019081573A1 (en) 2019-05-02
CA3079469A1 (en) 2019-05-02
WO2019081573A9 (en) 2020-05-28
MX2020004472A (en) 2020-08-06
EP3700891A1 (en) 2020-09-02
CN111511720A (en) 2020-08-07
KR20200081445A (en) 2020-07-07
IL274041A (en) 2020-06-30
BR112020008484A2 (en) 2020-10-20
US20210179577A1 (en) 2021-06-17
MA50448A (en) 2020-09-02
AU2018356430A1 (en) 2020-04-30
EA202091028A1 (en) 2020-09-09
JOP20200077A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
IL272555A (en) Novel sulfonamide carboxamide compounds
IL273786A (en) Novel sulfonamide carboxamide compounds
IL271716A (en) Novel sulfonamide carboxamide compounds
IL272550A (en) Novel sulfonamide carboxamide compounds
ZA201808130B (en) Aromatic sulfonamide derivatives
IL275306A (en) Devices for ocular surgery
BR112016021682A2 (en) cenicriviroc for the treatment of fibrosis
IL274041A (en) Aromatic sulfonamide derivatives for the treatment of ischemic stroke
IL275482A (en) Esketamine for the treatment of depression
EP3525717C0 (en) Devices for tissue augmentation
ZA201900609B (en) Sulfonamides as gpr40- and gpr120-agonists
HK1247558A1 (en) Cenicriviroc for the treatment of fibrosis
PT3412667T (en) Cocrystal
IL274190A (en) Methods of treating an ischemic disease
IL266530A (en) Treatment for fibrosis
GB201800257D0 (en) New therapeutic uses
GB201703750D0 (en) Ceed 1
GB201712833D0 (en) Gamblers calcutor